medigraphic.com
ISSN 0016-3813 (Print)

2005, Number 5

<< Back Next >>

Gac Med Mex 2005; 141 (5)

Mortality in cardiogenic shock.

Martínez-Sánchez C, Chuquiure-Valenzuela E, Flores-Ramírez R, García-López S, Arias-Mendoza A, González-Pacheco H, Vieyra-Herrera G, Juárez-Herrera U, Lupi-Herrera E

Language: Spanish
References: 26
Page: 395-400
PDF size: 75.03 Kb.


ABSTRACT

Objective: Cardiogenic shock (CS) is one of principal causes of mortality after an acute myocardial infarction (MI). The objective of this study was to determine the principal causes that contribute to an increase in mortality in CS. Methods: We studied 155 consecutive patients with CS admitted to the Coronary Care Unit of the Instituto Nacional de Cardiología Ignacio Chávez from 1990-2002. Results: Patients older than 60 years with MI and diabetes mellitus presented a higher cardiovascular mortality (p‹0.001). Percutaneous coronary intervention (PCI) procedures decreased the cardiovascular mortality in CS as compared to those patients not submmitted to PCI (59% vs. 98%, p‹0.001). Conclusions: Mortality due to CS is still very high (80%). Previous MI and diabetes favor short-term mortality and the use of PCI suggests a clinical favourable trend in the reduction of mortality due to CS. PCI appears to be the most appropriate reperfusion procedure for treating CS.


REFERENCES

  1. Alpert JS, Becker RC. Cardiogenic Shock: Elements of Etiology Diagnosis, and therapy Clin Cardiol 1993;16:182-90.

  2. Hurtado BA, Santome JA, Fernandez BC, Cárdenas LM: Infarto Agudo del Miocardio con Choque cardiogénico. Arch Inst Cardiol Mex 1984;54:121-129.

  3. Moscucci M y Bates E. Cardiogenic Shock. Cardiology Clinics. 1995;13(3):391-406.

  4. Q’Neill WW. Angioplasty Therapy of Cardiogenic Shock: Are Random Red Trial Necessary? JAM Coll Cardiol. 1992;19:915-917.

  5. Bates ER,Topol. Limitation of Trombolytic Therapy for Acute Myocardial Infarction Complicated by Congestive Heart Failure and Cardiogenic Shock. JAM Coll Cardiol. 1991;18:1077-1084.

  6. Hochman JS. Cardiogenic Shock: Can We Save The Patient? ACC.Educational Highlights 1996;12:1-5.

  7. Hochman JS, Sleeper LA, Webb JG, Sanborm TA, White HD, Talley DT et al. Early revascularization in Acute Myocardial Infarction Complicated By Cardiogenic Shock. N Engl J Med. 1999;341:625-634.

  8. LEE L, Bates ER, Dittb. Percutaneous transluminal Coronary Angioplasty Improvtes Survival in Acute myocardial lnfarction Complicates By Cardiogenic Shock. Circulationn 1988,78:1345-1351.

  9. Hochman JS Boland J, Sleepterda, Prwaym, Brinicer: Current Spectrum of Cardiogenic Shock and Effect of Early Revascularization on mortality. Circulation 1995;91:873-881.

  10. Carleton SC. The Cardiovascular Effect of Sepsis. Cardiology Clinics. 1995;13(2):249-256.

  11. Alonso DR. Scheidt S, Post M, Killipt. Pathophysiology of Cardiogenic Shock. Quantification of Myocardial Necrosis, Clinical Pathological, And Electrocardiographic Correlations. Circulation 1973;48:588-596.

  12. Page DL, Cautfield JB, Kastor JA. Myocardial Changes Associated With Cardiogenic Shock. N Engl J Med. 1971;285:133-137.

  13. We I JK, Hutchins GM Buckley BH. Papillary musculite Rupture In fatal Myocardial infarction. A Potentially Treatable Form of Cardiogenic Shock. Ann Inter Med. 1979;90:149-153.

  14. Oliva P, Hammill S, Edwards W. Cardiac Rupture a clinically Predictable complication of acute myocardial infarction report of 70 cases with clinic pathologic correlation. J Am Coll Cardio. 1993;22:720-726.

  15. Lupi HE, González PH, Juárez HU, Chuquiure VE, Vierya HG, Martínez SC. La meta de reperfusión en los Síndromes Isquémicos Coronarios Agudos con Elevación del Segmento STo El gran paradigma. Arch Nal Cardiol Méx. 2002;1:311-349.

  16. Lupi HE. Registro Nacional de los Síndromes Isquémicos Coronarios Agudos. (RENASICA). Sociedad Mexicana de Cardiología. Arch Nal Cardiol Méx. 2002;72(2),S45-S64.

  17. Lupi HE, Abundes AV, Martínez AE. Choque Cardiogénico. 1 Consenso de Insuficiencia Cardiaca. Rev Mex Cardiol. 2000;11(2):254-269.

  18. Spss 1M 10.0 For Windows.

  19. Davison B. Trapp R. Basicand Clinicial Biostatistics. Third Edition USA. Mc Graw-Hill, 2001.

  20. Hasdai D, Topol Ej, Califf RM. Cardiogenic Shock Complicating Acute Coronary Syndromes. The Lancet, 2000;356:749-756.

  21. Juárez H.U, López CR, González PH,Martínez SC, Lasses L.A, Chuquiure VE. Nueva Terapia antitrombótica en el Tratamiento de Pacientes con Angor inestable. Arch Nal Cardiol Méx. 1998;68:157-158.

  22. Leier CV an Binkley PHF. Parenteral Support for Advanced Congestive Heart Failure. Prog Cardiov disease. 1998;41:207-224.

  23. Sambor T A, Sleeper La, Bates ER. Impact of Thrombolysis, Intra Aortic Balloon Pump Counterpulsation and Their Combination in The Cardiogenic Shock Complicating. Acute Myocardial lnfarction: A Report From The Shock Trial Registry. J Am Coll Cardiol. 2000; 3336(3):1123-1129.

  24. Goldberg R.J, Gore JM, Alaerr JS. Cardiogenic Shock After Acute Myocardial lnfarction. Incidence and Mortality From a Community-Wide Perspective, 1975 to 1988. N Eng J Med. 1991;325(16):1117-1122.

  25. Grines CL, Growme KF, Marco J. Primary Angioplasty in Myocardial lnfarction Study Group. A comparison of Immediate Angioplasty With Trombolytic Therapy For Acute Myocardial Infarction. N Engl J Med. 1993;328:673-679.

  26. Martínez-Ríos MA, Rosas PM, González PH et al. Comparison of reperfusion regimens with or without Tirofiban in ST-Elevation acute myocardial infarction. Am J Cardiol. 2004;93:280-287.




2020     |     www.medigraphic.com